High-fat diet obesity associated with insulin resistance increases cell proliferation, estrogen receptor, and PI3K proteins in rat ventral prostate

Journal of Andrology

Volumn 33, Issue 5, 2012, Pages 854-865

  Ribeiro, Daniele Lisboa ^a,b   Pinto, Maria Etelvina ^b   Rafacho, Alex ^b   Bosqueiro, José Roberto ^c   Maeda, Samantha Yuri ^b   Anselmo Franci, Janete Aparecida ^d   Taboga, Sebastião Roberto ^b   Góes, Rejane Maira ^b  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Androgen; Cell hyperplasia; Fatty diet

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; PHOSPHATIDYLINOSITOL 3 KINASE; TESTOSTERONE; ANDROGEN RECEPTOR; AROMATASE INHIBITOR; INSULIN; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, RAT; LETROZOLE; NITRILE; PROTEIN KINASE B; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; INCIDENCE; INSULIN RESISTANCE; LIPID DIET; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE VENTRAL LOBE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TESTOSTERONE BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECT; EPITHELIUM CELL; HYPERINSULINISM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE; PROSTATE TUMOR; STROMA CELL; TIME; WISTAR RAT;

ANIMALS; AROMATASE INHIBITORS; BLOTTING, WESTERN; CELL PROLIFERATION; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; ESTROGEN RECEPTOR BETA; HYPERINSULINISM; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; NITRILES; OBESITY; PHOSPHATIDYLINOSITOL 3-KINASE; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STROMAL CELLS; TESTOSTERONE; TIME FACTORS; TRIAZOLES;

EID: 84874411482     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.111.016089     Document Type: Article

References (63)

1. Aquila S, Sisci D, Gentile M, Middea E, Catalano S, Carpino A, Vittoria R, Ando S. Estrogen receptor (ER)α and ERβ are both expressed in human ejaculated spermatozoa: evidence of their direct interaction with phosphatidylinositol-3-OH kinase/Akt pathway. J Clin Endocrinol Metab. 2004;89:1443-1451.
2. Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010;16(10):2702-2708.
3. Bulun SE, Yang S, Fang Z, Gurates B, Tamura M. Role of aromatase in endometrial disease. J Steroid Biochem Mol Biol. 2001;79:19-25.
4. Cai LQ, McGinley JI, Zhu YS. Regulation of prostate 5a-reductase-2 gene expression and prostate weight by dietary fat and caloric intake in the rat. Prostate. 2006;66:738-748.
5. Cai X, Haleem R, Oram S, Cyriac J, Jiang F, Grayhack JT, Kozlowski JM, Wang Z. High-fat diet increases the weight of rat ventral prostate. Prostate. 2001;49:1-8.
6. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579-591.
7. Chen JQ, Brown TR, Russo J. Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochimi Biophys Acta. 2009;1793(7):1128-1143.
8. Corona G, Mannucci E, Schulman C, Petrone L, Mansani R, Cilotti A, Balercia G, Chiarini V, Forti G, Maggi M. Psychobiologic correlates of the metabolic syndrome associated sexual dysfunction. Eur Urol. 2006;50:595-604.
9. Corradi LS, Campus SGP, Santos FCA, Vilamaior PSL, Góes RM, Taboga SR. Long-term inhibition of 5-alpha reductase and aromatase changes the cellular and extracelular compartments in gerbil ventral prostate at different postnatal ages. Int J Exp Pathol. 2009a;90:79-94.
10. Corradi LS, Góes R, Vilamaior PSL, Taboga SR. Increased androgen receptor and remodeling in the prostatic stroma after the inhibition of 5-alpha reductase and aromatase in gerbil ventral prostate. Microsc Res Tech. 2009b;72(12):939-950.
11. Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Després JP, Bouchard C. Contribution of body fitness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE family study. J Clin Endocrinol Metab. 2000;85:1026-1031.
12. Cunha GR, Wang YZ, Hayward SW, Risbridger GP. Estrogenic effects on prostatic differentiation and carcinogenesis. Reprod Fertil Dev. 2001;13:285-296.
13. Damas-Souza DM, Oliveira CA, Carvalho HF. Insulin affects tissue organization and the kinetics of epithelial cell death in the rat ventral prostate after castration. J Androl. 2010;31(6):631-640.
14. Dunger DB, Ahmed ML, Ong KK. Effects of obesity on growth and puberty. Best Pract Res Clin Endocrinol Metab. 2005;19(3):375-390.
15. Ellem SJ, Risbridger GP. The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci. 2009;1155:174-186.
16. Ellem SJ, Risbridger GP. Aromatase and regulating the estrogen: androgen ratio in the prostate gland. J Steroid Biochem Mol Biol. 2010;118(4-5):246-251.
17. Escobar ELO, Gomes-Marcondes MCC, Carvalho HF. Dietary fatty acid quality affects AR and PPARγ levels and prostate growth. Prostate. 2009;69:548-558.
18. Francia-Farje LA, Silva DS, Volpato GT, Fernandes GS, Carnietto N, Cicogna AC, Kempinas Wde G. Sibutramine effects on the reproductive performance of pregnant overweight and nonoverweight rats. J Toxicol Environ Health A. 2010;73(13-14):985-990.
19. Frankenberry KA, Somasundar P, MsFadden DW, Vona-Davis LC. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg. 2004;188:560-565.
20. Hammarsten J, Damber JE, Karlsson M, Knutson T, Ljunggren O, Ohlsson C, Peeker R, Smith U, Mellstrom D. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2009;12:180-185.
21. Hammarsten J, Hogstedt B. Hyperinsulinemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41: 2887-2895.
22. Hammoud AO, Wilde N, Gibson M, Parks A, Carrell DT, Meikle AW. Male obesity and alteration in sperm parameters. Fertil Steril. 2008;90(6):2222-2225.
23. Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS. The pharmacology of letrozole. J Steroid Biochem Mol Biol. 2003;87: 35-45.
24. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst. 1998; 90:1637-1647.
25. Hoda MR, Popken G. Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells. BJU Int. 2008;102:383-438.
26. Horvath G, Leser G, Hahlin M, Henriksson M. Exon deletions and variants of human estrogen receptor mRNA in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer. 2000;10(2): 128-136.
27. Hsing AW, Reichardt JKV, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate. 2002;52:213-235.
28. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol. 2005;63: 239-250.
29. Kaur P, Shukla A, Gulta S. Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study. Carcinogenesis. 2008;29(11):2210-2217.
30. Kobayashi N, Barnard J, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff D, Cohen P, Aronson WJ. Effect of low-fat diet on development of prostate cancer and Akt phophorylation in the Hi-Myc transgenic mouse model. Cancer Res. 2008;68:3088-3073.
31. Landstrom M, Zhang JX, Hailmans G, Aman P, Bergh A, Damber JE, Manzur W, Wahala K, Adlercreutz H. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate. 1998;36:151-161.
32. Laukkanen JA, Laaksonen D, Niskanen L, Pukkala E, Hakkarainem A, Salonem J. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population based study. Cancer Epidemiol Biomark Prev. 2004;13:1646-1650.
33. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-Tor signal transduction pathways. Genes Dev. 2006;20:267-275.
34. MacDonald AA, Herbison GP, Showell M, Farquhar CM. The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum Reprod Update. 2010;16:293-311.
35. Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol. 2010;316(2):180-186.
36. Matos AFG, Moreira RO, Guedes EP. Aspectos neuroendócrinos da Síndrome Metabólica. Arq Bras Endocrinol. 2003;47:410-421.
37. McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH, Risbridger GP. Essential role for estrogen receptor beta in stromalepithelial regulation of prostatic hyperplasia. Endocrinology. 2007;148:566-574.
38. Nandeesh H. Insulin: a novel agent in the pathogenesis of prostate cancer. Int Urol Nephrol. 2009;41:267-272.
39. Nascimento AF, Sugizaki MM, Leopoldo AS, Lima-Leopoldo AP, Luvizotto RA, Nogueira CR, Cicogna AC. A hypercaloric pelletdiet cycle induces obesity and co-morbidities in Wistar rats. Arq Bras Endocrinol Metabol. 2008;52(6):968-974.
40. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51:199-203.
41. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2009;182:S27-S31.
42. Patry G, Jarvi K, Grober ED, Lo KC. Use of aromatase inhibitor letrozole to treat male infertility. Fertil Steril. 2009;92: 829.e1-2.
43. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008;73:233-244.
44. Rafacho A, Giozzet VA, Boschero AC, Bosqueiro JR. Functional alterations in endocrine pancreas of rats with different degrees of dexamethasone-induced insulin resistance. Pancreas. 2008;36: 284-293.
45. Rafacho A, Quallio S, Ribeiro DL, Taboga SR, Paula FM, Boschero AC, Bosqueiro JR. The adaptive compensations in endocrine pancreas from glucocorticoid-treated rats are reversible after the interruption of treatment. Acta Physiol. 2010;200(3):223-235.
46. Rahman NU, Phonsombat S, Bochinski D, Carrion RE, Nunes L, Lue TF. An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. BJU Int. 2007;100(3): 658-663.
47. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res. 2009;15(15):4799-4805.
48. Scarano WR, Cordeiro RS, Góes RM, Taboga SR. Intraepithelial alterations in the guinea pig lateral prostate at different ages after estradiol treatment. J Submicrosc Cytol Pathol. 2004;36(2):141-148.
49. Scott AM, Atwater I, Rojas E. A method for the simultaneous measurement of insulin release and B cell membrane potential in single mouse islets of Langerhans. Diabetologia. 1981;21:470-475.
50. Séralini EG, Moslemi S. Aromatase inhibitors: past, present and future. Mol Cell Endocrinol. 2001;178:117-131.
51. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res. 2008;14(16):5228-5235.
52. Shappel SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology commitee. Cancer Res. 2004;61:2270-2305.
53. Singh PB, Matanhelia SS, Martin FL. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer. 2008;44:928-936.
54. Stanworth RD, Jones TH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res. 2009;37:74-90.
55. Sun M, Paciga JE, Feldman RT, Yunn Z, Coppola D, Lu YY, Shelley SA, Nicosin SV, Cheng JQ. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptorα (ERα) via interaction between Erα and PI3K. Cancer Res. 2001;52:5985-5991.
56. Suzuki K, Okazaki TL, Kurokawa K. Effects of dual inhibition of 5-alpha reductase and aromatase on spontaneously developed canine prostatic hypertrophy. Prostate. 1998;37:70-76.
57. Travis RC, Spencer EA, Allen NE, Appleby PN, Roddam AW, Overvad K, Johnsen NF, Olsen A, Kaaks R, Linseisen J. Plasma phyto-oestrogens and prostate cancer in the European prospective investigation into cancer and nutrition. Br J Cancer. 2009;100(11): 1817-1823.
58. Tymchuk CN, Tessler SB, Aronson WJ, Barnard RJ. Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer. 1998;31:127-131.
59. Vikram A, Jena G, Ramarao P. Insulin-resistance and benign prostatic hyperplasia: the connection. Eur J Pharmacol. 2010;641(2-3): 75-81.
60. Wake DJ, Strand M, Rask E, Westerbacka J, Livingstone DE, Soderberg S, Andrew R, Yki-Jarvinen H, Olsson T, Walker BR. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol. 2007;66(3):440-446.
61. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A. 2001;98:6330-6335.
62. Wickman S, Saukkone T, Dunkel L. The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. Eur J Endocrinol. 2002;146:339-346.
63. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, Rosenfeld RS. Plasma free and non-sex-hormone-binding-globulinbound testosterone are decreased in obese men in proportion to their degree of obesity. J Endocrinol Metab. 1990;71(4):929-931.